We conducted a prospective, multi-institutional phase II biomarker study of EGFR mutated, advanced NSCLC patients treated with afatinib (West Japan Oncology Group [WJOG] 8114LTR). This evidence concerns the gene EGFR and non-small cell lung carcinoma.